Aptevo Therapeutics Inc (NASDAQ:APVO) insider Marvin L. White sold 100,000 shares of the stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $2.93, for a total value of $293,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
APVO stock opened at $3.05 on Friday. The company has a quick ratio of 5.08, a current ratio of 5.14 and a debt-to-equity ratio of 0.19. Aptevo Therapeutics Inc has a 1-year low of $1.15 and a 1-year high of $4.85.
A number of large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC lifted its holdings in Aptevo Therapeutics by 87.2% during the 4th quarter. Acadian Asset Management LLC now owns 67,799 shares of the biotechnology company’s stock worth $287,000 after buying an additional 31,578 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Aptevo Therapeutics by 8.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock worth $2,187,000 after buying an additional 78,109 shares during the last quarter. Virtu Financial LLC bought a new position in Aptevo Therapeutics during the 4th quarter worth approximately $690,000. Victory Capital Management Inc. bought a new position in Aptevo Therapeutics during the 4th quarter worth approximately $827,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Aptevo Therapeutics by 411.8% in the 4th quarter. Renaissance Technologies LLC now owns 428,400 shares of the biotechnology company’s stock worth $1,816,000 after purchasing an additional 344,700 shares during the last quarter. 33.04% of the stock is currently owned by institutional investors.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.